TLSI logo

TRISALUS LIFE SCIENCES INC

TLSINASDAQ
🏆 #3510 by market capEarnings Nov 12US Equity
$4.26▼ $0.11 (−2.63%)
Market closed · at close
🔔
Track TLSI
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.6%
7d▼ 14.5%
14d▼ 13.5%
30d▼ 13.9%
ytd▼ 38.8%
1y▼ 7.9%
🏦Market Cap
$262M
Small Cap
📈Revenue Growth (YoY)
+53.4%
High Growth
📊Gross Margin
85.8%
High
💵FCF Margin
-66.3%
Thin
⚖️P/S Ratio
5.8x
Fair
Otter Score
60
Fair

Trading Snapshot

Day Range
$4.22 – $4.31
52-Week Range
$2.20 – $7.95
Volume
$3.82B
Avg Volume
$3.02B
Shares Outstanding
61.6M
Next Earnings
Nov 21, 2026

Fundamentals Snapshot

Annual Revenue
$45M
Last Q Revenue
$11M
P/E Ratio
-3.3
P/S Ratio
5.8x
EPS (TTM)
$-0.48
Dividend Yield
0.00%
Dilution (1yr)
+76.8%

Why Investors Own TLSI

  • ✓High-growth profile — revenue up +36.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 26% gross margin and 22% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TLSI logo

TRISALUS LIFE SCIENCES INC

TLSI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$45M▲ +53.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
84.6%▼ −1.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$27M▼ −25.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▼ −54.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.8M▲ +76.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$14M▲ +$1M YoY
StockOtter · stockotter.space

About TRISALUS LIFE SCIENCES INC

TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$5.17
▲ +21.3% Upside
High Target$5.96
Low Target$4.06
Based on 16 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

TRISALUS LIFE SCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift TLSI price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

TRISALUS LIFE SCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.